Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 16/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.33 |
| ▸ | CTSD | P07339 | 5/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSE | P14091 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044737 | 0.90 | BACE1 (0.35) | BACE1BACE2CTSDCTSE | |
| SCHEMBL6044130 | 0.90 | NTRK1 (0.36) | NTRK1NTRK3BACE1BACE2CTSD | |
| SCHEMBL6044194 | 0.90 | BACE1 (0.37) | NTRK1NTRK3BACE1BACE2CTSD | |
| SCHEMBL6044685 | 0.89 | NTRK1 (0.36) | NTRK1NTRK3BACE1BACE2CTSD | |
| SCHEMBL6044023 | 0.88 | BACE1 (0.38) | BACE1BACE2CTSDCTSE | |
| SCHEMBL6043732 | 0.87 | BACE1 (0.37) | BACE1BACE2CTSD | |
| SCHEMBL6044138 | 0.86 | BACE1 (0.37) | BACE1BACE2CTSDCTSE | |
| SCHEMBL6043610 | 0.84 | BACE1 (0.37) | BACE1BACE2CTSD | |
| SCHEMBL6043930 | 0.81 | BACE1 (0.38) | BACE1BACE2CTSDCTSE | |
| SCHEMBL6043702 | 0.81 | BACE1 (0.37) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1430032-A2 | SUBSTITUTED AMIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027068-A2 | SUBSTITUTED AMINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | BACE1, APP, BACE2 | NTRK1 3411/4885NTRK3 2809/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.